Micrograph News and Research

RSS

Moderna’s coronavirus vaccine candidate shows promise in phase I trial

Moderna, who partnered with the National Institutes of Health, announced that its candidate vaccine appeared to be safe when administered to eight healthy volunteers. The vaccine also stimulated an immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19).

20 May 2020

Did SARS-CoV-2 adapt to humans long before the index case?

A new study from Canada and the U.S. suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have already been pre-adapted to human transmission when it emerged in late 2019, which means there may be lingering populations of progenitor SARS-CoV-2 adept for human transmission and coronavirus disease (COVID-19) re-emergence. The research is published on the preprint server bioRxiv in May 2020.

19 May 2020

New animal model for COVID-19

As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to ravage the world, scientists are frantically searching for a vaccine or new drug that will effectively counter the lethal effects of the virus that leads to COVID-19 disease.

19 May 2020

Potential new treatment approach to fatal COVID-19

Researchers from the University of Colorado Anschutz Medical Campus and Pathways Bioscience in the United States have found that activating a transcription factor involved in oxidative stress regulation, antiviral activity, and inflammation may serve as a new treatment approach to coronavirus disease 2019 (COVID-19).

18 May 2020

Novel insights on SARS-CoV-2 cell entry may inform further vaccine and treatment development

A research group from Harvard Medical School reported two cryo-electron microscopy structures derived from a single preparation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in their paper available on the preprint server bioRxiv. Understanding the nuances of prefusion and postfusion conformations shed light on viral cell entry and may, in turn, guide the development of vaccines and drugs.

18 May 2020

Oxford University vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

As the world continues to grapple with the coronavirus pandemic, many scientists, institutions, and pharmaceutical companies are working hard to develop an effective vaccine.

18 May 2020

Hot temperatures, air pressure, UV radiation may decrease COVID-19 incidence

A new scientific paper published on the preprint server medRxiv shows that the spread of COVID-19, the respiratory illness that has spread across the world to kill hundreds of thousands in 2020, shows that weather conditions reduce the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 May 2020

New insights into SARS-CoV-2 viral diversity

The first comprehensive, large-scale analysis available on the preprint server bioRxiv attempted to identify specific genomic signatures of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains within and across individual hosts – revealing recombination events, specific geographic profiles, as well as multi-strain and/or superinfections characteristic for the coronavirus disease (COVID-19) pandemic.

14 May 2020

Research reveals how long SARS-CoV-2 survives on surfaces, in feces and urine

A new study published on the preprint server medRxiv* in May 2020 shows that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease can remain viable for a maximum of one week on smooth environmental surfaces, for several hours in human feces, and for a maximum of 4 days in human urine. This knowledge could help guide disinfection policies to control the virus spread.

14 May 2020

Lessons for COVID-19 from 2009 H1N1

The world has experienced many outbreaks of viral diseases. Over the past two decades, we have also seen the emergence of zoonotic human respiratory coronaviruses with pandemic potential.

13 May 2020

Researchers identify CoV Mac1 proteins as a potential SARS-CoV-2 drug target

A recent study by researchers at the University of Kansas and published on the preprint server bioRxiv* reveals that Mac1 protein implicated in the infection process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a strikingly similar structure and activity in all coronaviruses – suggesting that possible future treatments targeting this protein may exert broad antiviral activity.

13 May 2020

Placentas of pregnant women with COVID-19 showed abnormalities

A study conducted by researchers at Northwestern University, Chicago, has found that the placentas of pregnant women who were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) showed abnormalities, compared with those of uninfected women.

13 May 2020

A 'multi-omics' approach to the development of drugs against COVID-19

A new study published on the preprint server medRxiv* in May 2020 reports a multi-omics approach that could make it easier to develop drugs that are effective against COVID-19.

12 May 2020

SARS-CoV-2 cell entry affinity varies across different host species

A new study from India, currently available on the preprint server bioRxiv*, estimated the probability and readiness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect cells of different animal species – and revealed many of them that could act as disease carriers.

12 May 2020

Researchers show how nanocellulose form highly robust materials

Cohesion, the ability to keep things together, from the scale of nanoparticles to building sites is inherent to these nanofibrils, which can act as mortar to a nearly infinite type of particles as described in the study.

12 May 2020

Collaborative approach is essential to speed up COVID-19 vaccine candidates, say NIH experts

A harmonized and collaborative approach to the clinical testing, scale-up and distribution of candidate vaccines to prevent COVID-19 is essential, scientific leaders write in a perspective published today in Science.

12 May 2020

No evidence COVID-19 is spread by fecal-oral transmission

A new study published on the preprint server medRxiv* in May 2020 shows that in patients who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pharyngeal and fecal samples, the virus persists longer in the fecal samples than in the pharyngeal samples. However, fecal-oral transmission does not appear to occur.

10 May 2020

Neutralizing SARS-CoV-2 via S protein

A new study published on the preprint server bioRxiv* in May 2020 reports on a method to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by destroying its main spike protein, which is responsible for attachment to the host cell membrane.

10 May 2020

Low-molecular-weight drugs could help against COVID-19 says study

Chinese researchers have worked on using existing low molecular weight drugs to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

10 May 2020

Study shows COVID-19 vulnerability is highly dependent on host genetic architecture

A new US study available on the preprint server medRxiv reveals certain genetic variations that are associated with infection susceptibility and diverse clinical presentation of coronavirus disease (COVID-19) – including asymptomatic cases and severe forms of the disease in younger patients.

10 May 2020